BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 15, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

3D model of coronavirus spike

Not yet a pandemic, 2019-nCoV has echoes of MERS, SARS, flu

Feb. 5, 2020
By Anette Breindl
The drug screens prompted by the SARS and MERS outbreaks have been useful for quickly identifying drug candidates. But in terms of their epidemiology, “SARS and MERS were different from this coronavirus,” Allison McGeer explained at a Feb. 3 webinar by Evercore ISI.
Read More

Gilead investor sentiment remains flat amid continued focus on next steps

Feb. 5, 2020
By Michael Fitzhugh
Modest revenue growth and a 2020 outlook that left analysts uninspired about its near-term prospects pushed Gilead Sciences Inc. shares (NASDAQ:GILD) down about 2% to close Feb. 5 at $65.87, despite growing sales of its HIV medicine, Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide), and what CEO Daniel O'Day called "a sense of urgency" around further business development.
Read More

Regulatory front for Feb. 5, 2020

Feb. 5, 2020
The latest global regulatory news, changes and updates affecting biopharma, including: Raregen, Sandoz, United.
Read More
Coronavirus microscopic model
Ebola, malaria, HIV, TCM

Researchers cast wide net for rapid-draw weapons in 2019-nCoV fight

Feb. 4, 2020
By Anette Breindl
At this very early point in the emerging 2019-nCoV outbreak, knowledge about the virus is insufficient to predict what shape that outbreak will ultimately take. But knowledge about the virus is accumulating at remarkable speed, and experience with other viruses is helping to shape the response to the newest coronavirus threat. 2019-nCoV, sometimes called Wuhan coronavirus after its source, is the third coronavirus after SARS-CoV and MERS-CoV with the potential to cause serious illness and death that has emerged since the beginning of the 21st century.
Read More

Preventing a U.S. outbreak: Emergency declaration leads to hunt for more funding

Feb. 4, 2020
By Mari Serebrov
Now that U.S. Health and Human Services (HHS) Secretary Alex Azar has declared a nationwide public health emergency due to the 2019 novel coronavirus (2019-nCoV), HHS is saying it may need more money to help it be as proactive and aggressive as possible in detecting the virus and containing an outbreak.
Read More
Traditional Chinese medicine illustration

Coronavirus: Chinese researchers claim TCM herbal remedy could ‘inhibit’ 2019-nCoV

Feb. 4, 2020
By Cornelia Zou
HONG KONG – In another example that communication is proving as difficult as containment in the current coronavirus outbreak, China’s state media reported, to increasing skepticism, that a traditional Chinese medicine (TCM) oral liquid could inhibit the new coronavirus.
Read More

Other news to note for Feb. 4, 2020

Feb. 4, 2020
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Advaccine, Anticancer, Asahi Kasei, Aspen, Avacta, BGI, Biolexis, Celularity, Clover, Curetis, Curevac, Daewoong, Duke-National University, Horizon, Inovio, Novartis, Outlook, Oxford Gene Technology, Sandoz, Sorrento, Sysmex, Takeda, Veloxis, Wuhan Institute of Virology, Wuxi Biologics.
Read More

Regulatory front for Feb. 4, 2020

Feb. 4, 2020
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: GE Healthcare.
Read More

Other news to note for Feb. 4, 2020

Feb. 4, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aevi Genomics, Anika, Anteros, Athenex, Arthrosurface, Beijing CC-Pharming, Biomotiv, Biosense Webster, BMS, Boehringer, Cerecor, Contrafect, Cormedix, CNS Pharmaceuticals, Equinox, Eyepoint, FSD, Genekam, Ibio, Inprother, Levena, Mablytics, Navrogen, Pattern Bioscience, Plex, Porton Pharma, Q Biomed, Rhythm AI, Salarius, Samus, Sirion, Solarvest, Syntrix, Theratechnologies, Trefoil, Trianni.
Read More
2-3-Azar-HHS.png

HHS declares public health emergency in part because CDC test for coronavirus unreliable

Feb. 3, 2020
By Mark McCarty
The U.S. Department of Health and Human Services has declared a public health emergency in the U.S. over the coronavirus in part because a government diagnostic for the virus yields inconsistent results, a fact that may spur the life sciences to provide a solution.
Read More
Previous 1 2 … 530 531 532 533 534 535 536 537 538 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 14, 2026.
  • Illustration of a glowing circle to represent circRNA

    ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

    BioWorld
    Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
  • Brain maze

    Alzheimer’s, beyond the brain

    BioWorld
    Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 12, 2026
  • Test tubes, dropper and capsules

    Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

    BioWorld
    In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing